ASX Announcements
Atlas Arteria (ASX: ALX) – Releases Bidder’s Statement Number 89
IFM Global Infrastructure Fund has launched a formal takeover bid for Atlas Arteria Limited, with Diamond Infraco 1 Pty Ltd acting as the vehicle...
Clinuvel Pharmaceuticals (ASX: CUV) – FDA Relaxes SCENESSE Postmarketing Requirements
Clinuvel Pharmaceuticals has secured a significant regulatory milestone with the FDA's removal of a cardiac repolarization study requirement from...
Megaport (ASX: MP1) – Megaport Secures Three-Year Compute Contract
Megaport Limited has secured a significant three-year compute contract for its subsidiary Latitude.sh, valued at AUD$35.4 million with annualized...
NEXTDC (ASX: NXT) – NEXTDC Opens Retail Entitlement Offer
NEXTDC Limited opened its retail entitlement offer today, inviting eligible shareholders to subscribe for new fully paid ordinary shares at A$12.70...
NEXTDC (ASX: NXT) – Files Retail Offer Booklet and Eligibility Letters
NEXTDC Limited has launched a fully underwritten accelerated entitlement offer, seeking to raise approximately A$1.5 billion to fund its growth...
Scalare Partners Holdings (ASX: SCP) – SCP Files Quarterly Activities Report
Scalare Partners Holdings Limited reported another quarter of strong financial momentum, with revenue receipts of $5.26 million in the March 2026...
Nickel Industries (ASX: NIC) – Nickel Industries Files 2025 Annual Report
Nickel Industries has successfully issued US$800 million in senior unsecured notes, a financial milestone that materially extends the company's debt...
BrainChip Holdings (ASX: BRN) – Q10 2026 Quarterly Activities Report
BrainChip Holdings Limited provided its quarterly activities report for the period ending 31 March 2026, with notable progress on production...
Clinuvel Pharmaceuticals (ASX: CUV) – Final EMA Scientific Advice Vitiligo Phase III
Clinuvel Pharmaceuticals has received final regulatory guidance from the European Medicines Agency on the design of its Phase III vitiligo trial,...
EVT (ASX: EVT) – EVT Releases First FY2026 Update
EVT Limited expects to deliver normalised EBITDA growth for the full year ending 30 June 2026, maintaining growth guidance despite a range of...